AI-driven neoantigen identification: a comprehensive review from somatic variant calling to T cell recognition.
BACKGROUND: Neoantigens-tumor-specific peptides generated by somatic mutations-are central targets of effective anticancer T cell immunity and underpin the clinical success of immune checkpoint blockade and personalized cancer vaccines. Immunopeptidomics provides essential ground truth, revealing that only a small fraction of genomically predicted candidates are naturally presented and uncovering noncanonical antigen sources, including splice variants, post-translational modifications, and noncoding regions.
BACKGROUND: Neoantigens-tumor-specific peptides generated by somatic mutations-are central targets of effective anticancer T cell immunity and underpin the clinical success of immune checkpoint blockade and personalized cancer vaccines. Immunopeptidomics provides essential ground truth, revealing that only a small fraction of genomically predicted candidates are naturally presented and uncovering noncanonical antigen sources, including splice variants, post-translational modifications, and noncoding regions.
What the study was
- Study design
- Validation study
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Journal of translational medicine
Why it surfaced
Relevant Precision oncology and genomic medicine study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.